Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Brigatinib
Related studies linked through entity extraction aliases.
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
- Status
- COMPLETED
- Phase
- N/A
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
- Status
- COMPLETED
- Phase
- PHASE3
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2